Despite a growing number of approved monoclonal antibodies targeting respiratory diseases, none are delivered by inhalation. All are administered systemically, restricting access to the most severe patients and requiring high doses with significant side effects. Inhalation could unlock lower doses and broader patient populations – but nebulization damages antibodies, and no validated solution currently exists.

SoteriaBio is a French pre-clinical stage biotech company developing a proprietary technology platform enabling the inhaled delivery of monoclonal antibodies for respiratory diseases. Backed $4M in equity seed funding and grants, SoteriaBio has demonstrated in vivo proof of concept showing complete lung distribution, significantly higher local concentration versus systemic injection, and therapeutic efficacy in preclinical asthma and COVID models.

SoteriaBio is actively seeking partnerships with companies developing or commercializing monoclonal antibodies for respiratory diseases, as well as opportunities to build its own inhaled biologic pipeline.

Originating from MedXCell SA (a Swiss Venture Builder) and academic collaborations with EPFL and ICGM/CNRS, SoteriaBio is led by Anh Nguyen, founder of MedinCell (EURONEXT: MEDCL). The company operates in Montpellier (France) and Montreux (Switzerland).

Oncovita, a Paris-based biotech spin-off from the Institut Pasteur, is developing a next-generation immunotherapy platform based on a genetically modified measles vaccine–derived virus. Its lead candidate, MVdeltaC, an « in situ » immunotherapy is in pre-IND development phase and will be first developped in two high unmet medical need diseases: Pleural Mesothelioma and in Triple Negative Breast Cancer.

The VECTrans® technology exploits specific receptors selected for their high uptake/endocytosis and constitutive recycling capacity, thereby allowing significant intracellular transport and accumulation of therapeutic or imaging agents. Once the vector moiety of a vector-payload complex is locked onto the appropriate receptor at the surface of BBB endothelial cells, cancer cells or any target cell type expressing such receptors, the vector-payload complex undergoes rapid internalisation and subsequent intra/transcellular trafficking. This ultimately leads to payload delivery into cells and across the BBB into the brain via transport and transcytosis processes respectively thus modifying pharmacokinetic (PK) and distribution profile of therapeutic or imaging candidates.

Algenscribe is a pre-clinical stage biotechnology company developing a first-in-class Gene Replacement platform. The flexible platform aims to improve the efficiency and quality of Gene Editing from single bases to multi-kilobase replacements.

Algenscribe’s platform tackles technological challenges in gene editing:
1°) Boosts Efficiency: Dramatically increases gene replacement rates
2°) Enhances Precision: Minimizes nuclease-induced mutations
3°) Full-Scale Flexibility: Edits from single bases to multi-kilobase insertions
4°) Versatile Utility: Spans therapeutics and bioproduction
5°) Non-viral: Bypasses AAV-related delivery constraints.